Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019

dc.contributor.authorBelkacemi, Yazid
dc.contributor.authorSio, Torence T.
dc.contributor.authorColson-Durand, Laurianne
dc.contributor.authorOnal, Cem
dc.contributor.authorVilla, Salvador
dc.contributor.authorAnacak, Yavuz
dc.contributor.authorKrengli, Marco
dc.contributor.authorThariat, Juliette
dc.contributor.authorUgurluer, Gamze
dc.contributor.authorMiller, Robert C.
dc.contributor.authorMirimanoft, Rene-Olivier
dc.contributor.authorOzsahin, Mahmut
dc.contributor.authorTo, Nhu Hanh
dc.contributor.orcID0000-0002-2742-9021en_US
dc.contributor.pubmedID30819450en_US
dc.contributor.researcherIDD-5195-2014en_US
dc.date.accessioned2021-02-25T08:29:20Z
dc.date.available2021-02-25T08:29:20Z
dc.date.issued2019
dc.description.abstractPrimary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic options. In the literature, many EN-NHL types were reported from limited series which only allowed narrow views for elucidating prognostic factors and defining the role of loco-regional therapies in the era of new systemic and biologically targeted therapies. The Rare Cancer Network (RCN), an international multidisciplinary consortium, has published a number of reports on several EN-NHL sites which included many gland locations. In this review, we will focus on the recent literature for a selected number of EN-NHL types in both exocrine and endocrine gland locations. We aim to provide renewed and clear messages for the best practice in 2019 for diagnosis, histopathology, treatments, and also their prognostic implications. We believe that better understanding of molecular and genetic characteristics of these particular diseases is crucial for an appropriate management in the era of personalized treatment developments.en_US
dc.identifier.endpage19en_US
dc.identifier.issn1040-8428en_US
dc.identifier.scopus2-s2.0-85060303755en_US
dc.identifier.startpage8en_US
dc.identifier.urihttp://hdl.handle.net/11727/5393
dc.identifier.volume135en_US
dc.identifier.wos000461262800002en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.critrevonc.2019.01.005en_US
dc.relation.journalCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLymphomaen_US
dc.subjectExtranodal non-Hodgkinlymphomaen_US
dc.subjectGlandsen_US
dc.subjectRadiation therapyen_US
dc.subjectClinical practiceen_US
dc.subjectRare canceren_US
dc.subjectRituximaben_US
dc.titlePrimary extranodal lymphoma of the glands. Literature review and options for best practice in 2019en_US
dc.typereviewen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: